Results 261 to 270 of about 115,437 (312)

PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma

Advanced Science, EarlyView.
Integrated scRNA‐seq, scTCR‐seq analysis, and functional assays identify PRDM1+ malignant epithelial cells with hyper lipid peroxidation characteristics that demonstrate reduced responsiveness to the nICRT treatment. Principal factor PRDM1 activates cysteine metabolism genes to modulate lipid peroxidation (an intrinsic cellular pathway related to ...
Dijian Shen, Rui Li, Yong She, Xuefei Liu, Yuanyang Huang, Yongling Ji, Keying Chen, Zhengbo Song, Runzhe Chen, Xuan Li, Qi Zhao, Qixun Chen, Ming Chen   +12 more
wiley   +1 more source

Roles of Tumor-Infiltrating Lymphocytes and Antitumor Immune Responses as Predictive and Prognostic Markers in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy. [PDF]

Int J Mol Sci
Kim R, Kin T, Arihiro K.
europepmc   +1 more source

The role of tumor-infiltrating lymphocytes and depth of invasion in T1 bladder cancer: a retrospective analysis. [PDF]

BMC Urol
Yaprak Bayrak B, Dogan HN, Teke K, Yuvak H, Dillioglugil O.   +4 more
europepmc   +1 more source

Decoding tumor-infiltrating lymphocytes heterogeneity in ductal carcinoma in situ: immune microenvironment dynamics and prognostic insights. [PDF]

Discov Oncol
Wang L, Yang Y, Song Y, Zeng J, Zheng H, Wu X.   +5 more
europepmc   +1 more source

Integrative prognostic model incorporating high mobility group box 1 subcellular localization and tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma. [PDF]

Diagn Pathol
Liu Y, Shimasaki M, Kumagai M, Han J, Shioya A, Sakurai M, Uramoto H, Yamada S.   +7 more
europepmc   +1 more source

Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. [PDF]

Nat Med
Lowery FJ, Goff SL, Gasmi B, Parkhurst MR, Ratnam NM, Halas HK, Shelton TE, Langhan MM, Bhasin A, Dinerman AJ, Dulemba V, Goldlust IS, Gustafson AM, Hakim AA, Hitscherich KJ, Kenney LM, Levy L, Rault-Wang JG, Bera A, Ray S, Seavey CD, Hoang CD, Hernandez JM, Gartner JJ, Sindiri S, Prickett TD, McIntyre LS, Krishna S, Robbins PF, Klemen ND, Kwong MLM, Yang JC, Rosenberg SA.   +32 more
europepmc   +1 more source

AI-detected tumor-infiltrating lymphocytes for predicting outcomes in anti-PD1 based treated melanoma

Schuiveling M, van Duin IA, Maat Lt, van der Weerd JC, Verheijden RJ, van den Berkmortel F, Blank CU, Breimer GE, Burgers FH, Boers-Sonderen M, van den Eertwegh AJM, de Groot JWB, Haanen JB, Hospers GA, Kapiteijn E, Piersma D, Vreugdenhil G, Westgeest H, Schrader AM, Pluim J, van Diest PJ, Veta M, Suijkerbuijk KP, Blokx W.   +23 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tumor-Infiltrating Lymphocytes

The Cancer Journal, 2015
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) in combination with lymphodepletion and high-dose interleukin 2 has shown reproducible objective response rates of approximately 50% in patients with highly advanced, refractory metastatic melanoma.
Michal J, Besser, Ronnie, Shapira-Frommer, Jacob, Schachter   +2 more
openaire   +3 more sources